TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9834004
Drug: Innovator carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovator carbamazepine formulation
Study: 2557513
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium diethyldithiocarbamate (DTC)
Study: 8084808
Drug: Acebutolol 400
Normalized name: acebutolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 400 mg daily
Study: 336378
Drug: Acebutolol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 600 mg daily
Study: 336378
Drug: Acebutolol 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 1200 mg daily
Study: 31729607
Drug: Buccal mucosal-advancement
Normalized name: Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal mucosal-advancement flap
Study: 31060374
Drug: Esmolol (β1‐AR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (β1‐AR blocker)
Study: 26712287
Drug: Bupivacaine 0.25%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25%, 1 mL/kg for caudal epidural block
Study: 26712287
Drug: Bupivacaine 0.25%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25%, 1 mL/kg with IV midazolam 0.1 mg/kg
Study: 26712287
Drug: Bupivacaine 0.25%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25%, 1 mL/kg with IV midazolam 0.1 mg/kg and ketamine 0.3 mg/kg
Study: 15578395
Drug: High-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose treatment with IFN (10 MU every 2 days) and ribavirin (1-1.2 g/day)
Study: 11410923
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MUP parameters
Study: 9400771
Drug: Chemoreduction with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoreduction with vincristine, etoposide, and carboplatin (VEC) for 6 cycles + adjuvant treatment (AT)
Study: 9400771
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment (AT)
Study: 3472467
Drug: Prostaglandin gel
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin gel cervical ripening followed by aggressive induction of labor and delivery
Study: 26523442
Drug: 38 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38 Gy RBE in 5 treatments (hypofractionated)
Study: 26523442
Drug: 79.2 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 79.2 Gy RBE in 44 treatments (standard fractionated)
Study: 26773800
Drug: Augmentation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation group (AG)
Study: 23446076
Drug: Alfentanil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 15 mcg/kg
Study: 22845044
Drug: BTDS 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTDS 10 with ketoconazole 200 mg twice daily
Study: 18060958
Drug: Telephone-administered Pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered Pelvic Floor Distress Inventory (PFDI)
Study: 18060958
Drug: Telephone-administered Pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered Pelvic Floor Impact Questionnaire (PFIQ)
Study: 12853351
Drug: Amifostine (910
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (910 mg/m2) with carboplatin and paclitaxel
Study: 8701411
Drug: Cyclic transdermal
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic transdermal E2 (50 micrograms/day for 21 days) plus medroxyprogesterone acetate (MPA) (10 mg/day from days 10 to 21)
Study: 8701411
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal E2 (50 micrograms/day for 28 days) plus MPA (10 mg/day from days 14 to 25)
Study: 1906532
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallium nitrate (200 mg/m2/d by continuous IV infusion for 5 days)
Study: 1906532
Drug: Etidronate (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (7.5 mg/kg as a 4-hour IV infusion for 5 days)
Study: 1906532
Drug: Etidronate (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (7.5 mg/kg)
Study: 2988108
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no fiber preparation)
Study: 18810296
Drug: HI PROT
Normalized name: NUTRITION SUPL BOOST HI PROTEIN/VAN LIQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: HI PROT (30% of total energy intake; 1.2-1.5 g/kg/d)
Study: 18810296
Drug: LO PROT
Approvals — FDA: no, EMA: no, PMDA: no
Description: LO PROT (15% of total energy intake; 0.5-0.7 g/kg/d)
Study: 9725505
Drug: beta-D-galactosidase pellets
Normalized name: BETA-D-GALACTOSIDASE
DrugBank: Tilactase (DB13761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-D-galactosidase pellets (100 u/ml)
Study: 2557219
Drug: Conventional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heparin (high-dose)
Study: 2557219
Drug: Conventional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heparin (low-dose)
Study: 2557219
Drug: Any form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any form of heparin therapy
Study: 239807
Drug: Pentazocine 30
Normalized name: pentazocine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 30 mg intramuscularly
Study: 1217684
Drug: Doxapram 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 60 mg intramuscularly
Study: 1217684
Drug: Doxapram 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 60 mg intramuscularly with Pentazocine 30 mg
Study: 24323569
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three triggers (alcohol consumption, presence of others smoking, negative affect)
Study: 25198082
Drug: Collagenase ointment
Normalized name: collagenase Topical Ointment
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collagenase ointment (CO)
Study: 17710398
Drug: Pegfilgrastim (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (6 mg single dose on day +5)
Study: 7578896
Drug: gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil (600 mg b.i.d.)
Study: 31897661
Drug: Oregovomab combined
Normalized name: Oregovomab
DrugBank: Oregovomab (DB04964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oregovomab combined with standard-of-care (SOC) therapy
Study: 31897661
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) therapy alone
Study: 25567069
Drug: Brazil nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nuts (288.75 µg/day) for 6 months
Study: 20813339
Drug: aMCI patients
Normalized name: Amcinonide
DrugBank: Amcinonide (DB00288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aMCI patients fulfilling biomarker criteria (CSF Aβ1‐42 ≤192 mg/mL or total‐tau/Aβ1‐42 >0.39)
Study: 12145593
Drug: Erythromycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (3 mg/kg intravenously over 30 minutes)
Study: 10673879
Drug: Cyclizine 50
Normalized name: cyclizine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclizine 50 mg i.v.
Study: 7562882
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg/day before breakfast) for 4 and 8 weeks
Study: 1834827
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of teicoplanin (6 mg/kg)
Study: 1834827
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of teicoplanin (6 mg/kg)
Study: 1834827
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered by the other route)
Study: 22371069
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine administered at 6 and 12 months (Group 1)
Study: 22371069
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine administered at 12 and 18 months (Group 2)
Study: 22371069
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine administered at 15 and 21 months (Group 3)
Study: 26190562
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg
Study: 9360756
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg OD)
Study: 3715789
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin formulations (300-650 mg)
Study: 29329996
Drug: Antiflatulent medication
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiflatulent medication
Study: 24673048
Drug: Warm acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm acupuncture therapy
Study: 24032192
Drug: Electroacupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture therapy
Study: 22153972
Drug: Pramipexole (4.25±0.38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (4.25±0.38 mg/day)
Study: 20514506
Drug: Pelvic autonomic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic autonomic nerve preservation during rectal cancer surgery
Study: 17680204
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received continuous infusion of fentanyl 30 microg x ml(‐1) and 2 mg/ml bupivacaine at a rate of 0.7 ml x h(‐1) for 72 h postoperatively
Study: 11889009
Drug: NTG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG group (48 hours of continuous NTG infusion)
Study: 9606617
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg once daily
Study: 2038931
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (3 mg/kg)
Study: 27544517
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) Control
Study: 21462240
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 60 mg XR once daily
Study: 9771983
Drug: TRUE Test
Normalized name: SunMark True Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRUE Test patch test (0.20 mg/cm2 for 48 h)
Study: 1004355
Drug: Molsidomine 2
Normalized name: molsidomine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 2 mg (sublingual or enteral)
Study: 1004355
Drug: Isosorbiddinitrate 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbiddinitrate 20 mg (sublingual)
Study: 23701973
Drug: Complex Ayurvedic
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex Ayurvedic treatment including tailored combinations of manual treatments, massages, dietary and lifestyle advice, nutritional supplements, yoga posture advice, and knee massage.
Study: 23701973
Drug: Conventional standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional standard care including self-care advice, pain medication, weight-loss advice (if overweight), and physiotherapy following current international guidelines.
Study: 23701973
Drug: Complex Ayurvedic
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex Ayurvedic treatment
Study: 22028817
Drug: Water Guard
Normalized name: HYPOCHLOROUS ACID 0.008 mg in 100 mL CUTANEOUS SPRAY [Water Guard Slightly Acidic Electrolyzed Hypochlorous Acid Water Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water Guard (sodium hypochlorite solution)
Study: 22028817
Drug: Sodium dichloroisocyanurate
Normalized name: Sodium dichloroisocyanurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium dichloroisocyanurate tablets (Aquatabs)
Study: 19019624
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (ASA 100 mg/d)
Study: 19019624
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel (ASA 100 mg/d + C 75 mg/d)
Study: 25219200
Drug: Rush immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rush immunotherapy (RIT)
Study: 3310722
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release morphine tablets (twice daily)
Study: 3310722
Drug: Aqueous morphine
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous morphine sulphate (4-hourly)
Study: 24074707
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) continued therapy
Study: 20522795
Drug: valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan (160 mg)
Study: 15478553
Drug: Artificial pneumothorax
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial pneumothorax (AP) during chemotherapy with reserve drugs
Study: 1343270
Drug: Combination therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy, ACE inhibitors, methyldopa
Study: 1679517
Drug: beta-blockers
Normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blockers
Study: 3909336
Drug: Single 1-g
Normalized name: bacitracin
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single 1-g intramuscular dose of aztreonam for acute uncomplicated cystitis
Study: 3909336
Drug: Multiple parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple parenteral doses of aztreonam (usually a five-day course of 1 g two or three times daily)
Study: 3909336
Drug: Multiple-dose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose therapy of aztreonam
Study: 3909336
Drug: Multiple-dose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose therapy of aztreonam in patients with multiply drug-resistant bacteria
Study: 29553453
Drug: Specific health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific health provider, receiving all medications from UNRWA, not turned away from clinic
Study: 29553453
Drug: Sex, age,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex, age, presence of disability, presence of complications, control status, kind of non-communicable disease, type of treatment provided, duration of non-communicable disease
Study: 24508026
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (50,000 IU weekly for 6 months)
Study: 15233669
Drug: interferon alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: interferon alpha‐2a 3 MIU thrice weekly
Study: 9572829
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement (135 mg/day)
Study: 8083793
Drug: Comprehensive oral
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive oral hygiene training program (3.5 hours per child)
Study: 8083793
Drug: Less comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less comprehensive oral hygiene training program (1.5 hours per child)
Study: 2479963
Drug: Immediate combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate combination chemotherapy and radiotherapy
Study: 2479963
Drug: Selective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective treatment (chemotherapy and/or radiotherapy as needed)
Study: 781336
Drug: Kaolin‐pectin suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaolin‐pectin suspension concentrate (Kao‐Con)
Study: 781336
Drug: Kaolin suspension
Normalized name: Kaolin
DrugBank: Kaolin (DB01575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaolin suspension
Study: 781336
Drug: Pectin suspension
Normalized name: KAOLIN 208.1 g in 1 L / PECTIN 8.8 g in 1 L ORAL SUSPENSION [Kaolin pectin Suspension]
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin suspension
Study: 23425732
Drug: TEG‐guided prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEG‐guided prophylaxis with escalating low‐molecular weight heparin (LMWH) up to 5,000 IU twice daily with the addition of aspirin
Study: 23425732
Drug: 5,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU of LMWH daily (control)
Study: 22087615
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement containing standardized lemon verbena extract (14% verbascoside, w/w) and fish oil omega-3 fatty acid
Study: 15017517
Drug: Sucralfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2 g, 10 mL suspension, twice a day for 6 weeks)
Study: 10834412
Drug: Nighttime-only insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nighttime-only insulin pump therapy
Study: 9076405
Drug: Plain ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain ascorbic acid (250 mg BID)
Study: 9076405
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release ascorbic acid (250 mg BID)
Study: 23702047
Drug: Hygiene promotion
Normalized name: PROMOTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygiene promotion and water treatment (HP&WT) and sanitation improvements in 'water-available' schools
Study: 23702047
Drug: Hygiene promotion
Normalized name: PROMOTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygiene promotion and water treatment (HP&WT) in 'water-available' schools
Study: 20050880
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 600 mg intravenous treatment for 21 days
Study: 15045685
Drug: Glipizide GITS
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide GITS (5 mg/d)
Study: 9051543
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (bolus 0.015 mg/kg followed by an infusion 0.003 mg/kg/hr)
Study: 9051543
Drug: Epidural oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural oxycodone (bolus 0.15 mg/kg followed by an infusion 0.03 mg/kg/hr)
Study: 9051543
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone (same dose as in the epidural group)
Study: 8112441
Drug: Bambuterol, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol, 10 mg once daily
Study: 8112441
Drug: Terbutaline, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline, 5 mg controlled release twice daily
Study: 2877127
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg indenolol once a day for 14 days
Study: 2877127
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg indenolol once a day for 14 days
Study: 27239902
Drug: Oral biographical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral biographical disclosure
Study: 27586686
Drug: Daily diary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily diary
Study: 15986443
Drug: Former oral
Normalized name: Triple Wormer Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Former oral contraceptive use
Study: 15986443
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive use, Norplant use, history of pregnancy, age at first pregnancy, lifetime numbers of pregnancies and live births
Study: 1513608
Drug: Loracarbef (15‐mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef (15‐mg/kg/day oral suspension or 200‐mg capsule taken twice daily for 10 days)
Study: 1513608
Drug: Penicillin VK
Normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin VK (20‐mg/kg/day oral suspension or 250‐mg capsule taken four times daily for 10 days)
Study: 6337473
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin ethylsuccinate (40 mg/kg/day in divided doses) for five days
Study: 29856768
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (supervised training sessions three times weekly and home exercise once weekly)
Study: 26813468
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g Hawaiian spirulina daily for three months
Study: 17502530
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus 400 IU of cholecalciferol (vitamin D) daily
Study: 12804729
Drug: Niacin ER
Normalized name: Niacin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin ER 1,000 mg/day
Study: 12804729
Drug: Niacin ER
Normalized name: Niacin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin ER 2,000 mg/day
Study: 1354938
Drug: Ibopamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (100 mg, 3 times daily)
Study: 1354938
Drug: Ibopamine (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (acute administration)
Study: 1354938
Drug: Ibopamine (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (chronic administration)
Study: 1354938
Drug: Ibopamine (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (acute and chronic administration)
Study: 6423720
Drug: Ethanol infusion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol infusion (0.4 g/kg)
Study: 6423720
Drug: Ethanol infusion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol infusion (0.8 g/kg)
Study: 30969797
Drug: Denosumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (120 mg)